Pharmacological studies of the new triazinoindole tompasline (3-(2-morpholinoethylthio)-1,2,4-triazino-[5, 6-b]indole dihydrochloride monohydrate) showed that it has high antihypoxic activity which is not species-specific. The activity of the agent is comparable to that of guthimine in hypoxic and circulatory hypoxia and is greater than that of guthimine in the "loading" model of hypoxia. The high efficacy of the protective effect of tompasline on the function of the sound analyzer allows this agent to be regarded as a potential specific antisurditant in acute sensorineural hearing loss. A preparative synthesis was developed for material of pharmacopeia quality, along with methods for its qualitative detection and quantitative estimation in substance and solutions, including biological fluids, which satisfy pharmacopeia requirements for therapeutic solution for intravenous injection. The technique for producing tompasline can be implemented more readily than the preparation of the antihypoxic agents guthimine and amtizol, which have not been yet introduced into production.The present report addresses our development of the first Russian antisurditant -tompasline -to be introduced into medical practice. The agent is (3-(2-morpholinoethylthio)-1,2,4-triazino[5,6-b]indole dihydrochloride monohydrate) (I), which has antihypoxic and anti-inflammatory activities [1,2].Compound I is one of the most effective antihypoxic agents among triazinoindole derivatives [3], which affect transmembrane ion transport [4]. Despite the fact that I is not the most active of these, it has a series of positive features, including a high therapeutic index, adequate solubility in water, and technical feasibility. I has been shown to have a wide spectrum of pharmacological activities, and is more active than guthimine and amtizol. Reports of several of the actions of I -analgesic, antiarrhythmic, antiaggregant, and neuroendocrine-optimizing in stress and hyperthermia -have been described in our previous reports (see the properties of the compound designed T-468) [5 -7]. Of particular note is the ability of I to relieve, in short periods of time (4 -5 days), acute sensorineural hearing loss and deafness [2].The aim of the present work was to study the antihypoxic action of I, as well as its protective effects on the auditory analyzer. We have undertaken experimental studies of the protective actions of I on auditory function in different pathological states. Despite the large number of studies addressing questions of the etiology, nature, and features of auditory afflictions, there are no pathogenetic substances for the treatment of acute sensorineural hearing loss. Given that the major pathogenetic component in the pathogenesis of sensorineural hearing loss in vascular, infectious, toxic, and other pathological actions on the hearing analyzer consists of intracochlear hypoxia [8,9], the most suitable approach to preventing functional degenerative changes in structures of the peripheral compartment of the auditory analyzer in acute sensorine...
